Transverse Medical, Inc., known for its POINT-GUARD™ Cerebral Embolic Protection device, is excited to announce the appointment of Ian T. Meredith, MD, to its Board of Directors. With over 35 years of experience in cardiology, Professor Meredith has a proven track record in clinical trials and the commercialization of various interventional devices.
Professor Ian Meredith, MD, has joined Transverse Medical’s Board of Directors as an Independent Member. He recently retired from Boston Scientific, where he served as Executive Vice President and Global Chief Medical Officer for six years. During his tenure, he oversaw medical affairs, trial strategy, and clinical science, playing a key role in Boston Scientific’s acquisition of Claret Medical and the Sentinel® Cerebral Embolic Protection technology.
Professor Meredith’s extensive background in the cardiovascular field, combined with his experience as a clinical and interventional cardiologist and his leadership role at Monash-Heart in Melbourne, positions him to significantly contribute to Transverse Medical’s business strategy and clinical planning.
Eric Goslau, President & CEO of Transverse Medical, expressed enthusiasm for Dr. Meredith’s corporate and clinical expertise, emphasizing the value he brings to the advancement of the POINT-GUARD™ device and the company’s future plans. Dr. Michael Reardon, Chief Medical Officer, highlighted Meredith’s impressive contributions to cardiovascular medicine and his expertise in clinical trial design.
Dr. Meredith shared his belief in the necessity of effective Cerebral Embolic Protection, particularly during invasive cardiac procedures, citing the profound impact of embolic strokes on patients’ lives. He emphasized his commitment to advancing medical technologies that can improve patient outcomes globally.
About POINT-GUARD™ and Transverse Medical, Inc.
Transverse Medical is an early-stage medical device company dedicated to developing the POINT-GUARD™ Cerebral Embolic Protection device. This innovative solution aims to provide full brain protection during Transcatheter Aortic Valve Replacement (TAVR), addressing the risk of stroke by preventing embolic debris from entering the cerebral blood flow. Currently in development, the POINT-GUARD™ has not yet received FDA approval for human use.
